Transplant vs bortezomib and LEN/DEX in multiple myeloma

Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib plus lenalidomide and dexamethasone (LEN/DEX) as the primary treatment for multiple myeloma, compared to induction therapy followed by transplant consolidation. In summary, the transplant adds to the care of myeloma patients and Dr Fonseca believes it will continue to be the main treatment used for multiple myeloma until new agents come along.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.

Share this video